Glaxo teams up with Galapagos on anti-infectives
LONDON Dec 10 (Reuters) - GlaxoSmithKline (GSK.L) has agreed an alliance with Belgium's Galapagos (GLPG.BR) to discover and develop new anti-infective medicines based on Galapagos's netural product drug delivery platform.
The two firms said on Monday that Galapagos would receive up to 3.5 million euros in technology access fees and up to 215 million euros in total payments for one marketed product, as well as up to a double-digit percentage royalty on sales of products from the alliance. (Reporting by Mark Potter, editing by Will Waterman)
- Putin dissolves state news agency, tightens grip on Russia media
- North Korea says Kim's powerful uncle dismissed for 'criminal acts'
- Thai PM calls snap election, protesters want power now |
- Record cold, ice grip U.S.; more snow to blanket East
- Protesters fell Lenin statue, tell Ukraine's president 'you're next'